<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02791945</url>
  </required_header>
  <id_info>
    <org_study_id>9236sc</org_study_id>
    <nct_id>NCT02791945</nct_id>
  </id_info>
  <brief_title>N-acetylcysteine Treatment of Alcohol Use Disorder In Veterans With TBI</brief_title>
  <acronym>NAC</acronym>
  <official_title>N-acetylcysteine Treatment of Alcohol Use Disorder In Veterans With TBI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northern California Institute of Research and Education</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>San Francisco Veterans Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute for Translational Neuroscience</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the project is to improve the care of Veterans with mild traumatic brain injury&#xD;
      (mTBI) and unhealthy alcohol use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot controlled clinical trial that aims to assess the efficacy of&#xD;
      N-acetylcysteine (NAC) to reduce alcohol use and improve brain injury symptoms in Veterans&#xD;
      with mTBI who consume alcohol at hazardous or harmful levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Percent of Heavy Drinking Days Per Week as Assessed by the Timeline Followback (TFLB)</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>The TLFB interview, using a calendar, asks participants to report the prior week's frequency of alcohol use on each day of the week.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in TBI Symptoms as Assessed by the Neurobehavioral Symptom Inventory (NSI)</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Participants indicate the extent to which each of the 22 symptoms has disturbed them in the previous 2 weeks on a 5-item scale (0-none to 4-severe). The NSI total score is the sum of severity ratings of the symptoms. The scores are summed to yield a total score ranging from 0 to 88, where the higher the point value, the greater (more severe) the symptoms</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change in Number of Standard Drinks Per Week as Assessed by the Timeline Followback (TLFB)</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>The TLFB interview, using a calendar, asks participants to report the prior week's frequency of alcohol use on each day of the week.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Traumatic Brain Injury (TBI)</condition>
  <condition>Hazardous and Harmful Alcohol Use</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-acetylcysteine capsules daily - up to 3200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules daily - up to 3200 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Medical Management Counseling</intervention_name>
    <description>Brief alcohol counseling</description>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>Experimental supplement</description>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female veterans&#xD;
&#xD;
          2. Ages 18-65 (inclusive)&#xD;
&#xD;
          3. A history of mTBI as defined by American Congress of Rehabilitation Medicine (ACRM),&#xD;
             in the chronic, stable phase of recovery (&gt;6 months from injury).&#xD;
&#xD;
          4. Current (past month [30 days]) Hazardous or Harmful Alcohol Use: Hazardous use is&#xD;
             drinking that meets NIAAA criteria: Current (past 30 day) weekly drinking, consisting&#xD;
             of an average of 15 standard drinks/week for men or 8 standard drinks/week for women.&#xD;
             Harmful use is drinking behavior that meets DSM-5 criteria mild AUD.&#xD;
&#xD;
          5. Participants must express a desire to reduce or stop alcohol use.&#xD;
&#xD;
          6. Female subjects that must have a negative urine pregnancy test and must be either&#xD;
             postmenopausal one year or practicing an effective birth control method.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unstable psychotic or bipolar disorders, dementia, or other psychiatric disorders&#xD;
             judged to be unstable in the clinical judgment of the PI or study physician.&#xD;
&#xD;
          2. Clinically significant unstable medical conditions, in the clinical judgment of the PI&#xD;
             or study physician.&#xD;
&#xD;
          3. Female patients who are pregnant or nursing.&#xD;
&#xD;
          4. Concurrent participation in another alcohol treatment study, or in any research study&#xD;
             involving medications.&#xD;
&#xD;
          5. Requiring acute medical detoxification from alcohol based on a score of 12 or more on&#xD;
             the Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-AD).&#xD;
&#xD;
          6. NAC use in the past week prior to study entry.&#xD;
&#xD;
          7. Use of AUD treatment medications (disulfiram, naltrexone, or acamprosate) within the&#xD;
             past week.&#xD;
&#xD;
          8. Participants who are legally mandated to participate in an alcohol treatment program.&#xD;
&#xD;
          9. Participants who have had a suicide attempt in the past 3 months or suicidal ideation,&#xD;
             with intent, in the 30 days prior to enrollment.&#xD;
&#xD;
         10. Participants who in the opinion of the investigator should not be enrolled in the&#xD;
             study because of the precautions, warnings or contraindications outlined in the NAC&#xD;
             package insert.&#xD;
&#xD;
         11. Participants with known hypersensitivity to acetylcysteine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven L. Batki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unviersity of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco VA Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 1, 2016</study_first_submitted>
  <study_first_submitted_qc>June 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2016</study_first_posted>
  <results_first_submitted>June 10, 2020</results_first_submitted>
  <results_first_submitted_qc>November 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 16, 2020</results_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TBI</keyword>
  <keyword>hazardous and harmful alcohol use</keyword>
  <keyword>Veterans</keyword>
  <keyword>co-occurring disorders</keyword>
  <keyword>pharmacotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT02791945/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT02791945/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>N-acetylcysteine</title>
          <description>N-acetylcysteine capsules daily - up to 3200 mg&#xD;
Medical Management Counseling: Brief alcohol counseling&#xD;
N-acetylcysteine: Experimental supplement</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo capsules daily - up to 3200 mg&#xD;
Medical Management Counseling: Brief alcohol counseling&#xD;
Placebo: Placebo comparator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>N-acetylcysteine</title>
          <description>N-acetylcysteine capsules daily - up to 3200 mg&#xD;
Medical Management Counseling: Brief alcohol counseling&#xD;
N-acetylcysteine: Experimental supplement</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo capsules daily - up to 3200 mg&#xD;
Medical Management Counseling: Brief alcohol counseling&#xD;
Placebo: Placebo comparator</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="8"/>
                    <measurement group_id="B2" value="54" spread="10"/>
                    <measurement group_id="B3" value="52" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Percent of Heavy Drinking Days Per Week as Assessed by the Timeline Followback (TFLB)</title>
        <description>The TLFB interview, using a calendar, asks participants to report the prior week's frequency of alcohol use on each day of the week.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine</title>
            <description>N-acetylcysteine capsules daily - up to 3200 mg&#xD;
Medical Management Counseling: Brief alcohol counseling&#xD;
N-acetylcysteine: Experimental supplement</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules daily - up to 3200 mg&#xD;
Medical Management Counseling: Brief alcohol counseling&#xD;
Placebo: Placebo comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent of Heavy Drinking Days Per Week as Assessed by the Timeline Followback (TFLB)</title>
          <description>The TLFB interview, using a calendar, asks participants to report the prior week's frequency of alcohol use on each day of the week.</description>
          <units>change in percent heavy drinking days/wk</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" spread="0.31"/>
                    <measurement group_id="O2" value="26.5" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in TBI Symptoms as Assessed by the Neurobehavioral Symptom Inventory (NSI)</title>
        <description>Participants indicate the extent to which each of the 22 symptoms has disturbed them in the previous 2 weeks on a 5-item scale (0-none to 4-severe). The NSI total score is the sum of severity ratings of the symptoms. The scores are summed to yield a total score ranging from 0 to 88, where the higher the point value, the greater (more severe) the symptoms</description>
        <time_frame>Baseline to Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine</title>
            <description>N-acetylcysteine capsules daily - up to 3200 mg&#xD;
Medical Management Counseling: Brief alcohol counseling&#xD;
N-acetylcysteine: Experimental supplement</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules daily - up to 3200 mg&#xD;
Medical Management Counseling: Brief alcohol counseling&#xD;
Placebo: Placebo comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change in TBI Symptoms as Assessed by the Neurobehavioral Symptom Inventory (NSI)</title>
          <description>Participants indicate the extent to which each of the 22 symptoms has disturbed them in the previous 2 weeks on a 5-item scale (0-none to 4-severe). The NSI total score is the sum of severity ratings of the symptoms. The scores are summed to yield a total score ranging from 0 to 88, where the higher the point value, the greater (more severe) the symptoms</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.44" spread="10.09"/>
                    <measurement group_id="O2" value="10" spread="10.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Number of Standard Drinks Per Week as Assessed by the Timeline Followback (TLFB)</title>
        <description>The TLFB interview, using a calendar, asks participants to report the prior week's frequency of alcohol use on each day of the week.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine</title>
            <description>N-acetylcysteine capsules daily - up to 3200 mg&#xD;
Medical Management Counseling: Brief alcohol counseling&#xD;
N-acetylcysteine: Experimental supplement</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules daily - up to 3200 mg&#xD;
Medical Management Counseling: Brief alcohol counseling&#xD;
Placebo: Placebo comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Standard Drinks Per Week as Assessed by the Timeline Followback (TLFB)</title>
          <description>The TLFB interview, using a calendar, asks participants to report the prior week's frequency of alcohol use on each day of the week.</description>
          <units>Standard drinks per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.75" spread="25.6"/>
                    <measurement group_id="O2" value="18.45" spread="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Over 12 weeks.</time_frame>
      <desc>We used the Adverse Event Symptom Checklist at every study visit (Visits 0 - 8 and 12), which assessed the most reported adverse events listed in the FDA Prescribing Information.</desc>
      <group_list>
        <group group_id="E1">
          <title>N-acetylcysteine</title>
          <description>N-acetylcysteine capsules daily - up to 3200 mg&#xD;
Medical Management Counseling: Brief alcohol counseling&#xD;
N-acetylcysteine: Experimental supplement</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo capsules daily - up to 3200 mg&#xD;
Medical Management Counseling: Brief alcohol counseling&#xD;
Placebo: Placebo comparator</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Inpatient hospitalization for self-reported &quot;broken back in 3 places&quot;.</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Inpatient hospitalization/5150 (&lt;72 hours) for suicidal threats while intoxicated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Upset stomach</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hives</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Steven L. Batki, MD</name_or_title>
      <organization>University of California, San Francisco/San Francisco VA Healthcare System</organization>
      <phone>415-221-4810 ext 23671</phone>
      <email>steven.batki@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

